When will the patents on AMABELZ expire, and when will AMABELZ go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	AMABELZ	estradiol; norethindrone acetate	TABLET;ORAL	203339-001	Jun 20, 2016	BX	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin	AMABELZ	estradiol; norethindrone acetate	TABLET;ORAL	203339-002	Jun 20, 2016	BX	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 9, 2026

Executive summary: AMABELZ is an FDA-approved fixed-dose hormone therapy for moderate to severe vasomotor symptoms associated with menopause. Investment upside is capped by (1) mature market dynamics for menopausal hormone therapy, (2) time-based loss of branded exclusivity and likely generic/authorized generic pressure as key patents and listed exclusivities expire, and (3) payer and channel risk for a lower-differentiation HRT portfolio product. Decision-grade diligence centers on Orange Book status (listed patents and patent expiration dates), exclusivity periods tied to the NDA/505(b)(2) reference chain, and any Paragraph IV or settlement-driven generic entry risk.

What is AMABELZ and what does it treat?

AMABELZ is a branded oral combination of estradiol hemihydrate and norethindrone acetate for moderate to severe vasomotor symptoms due to menopause in women with a uterus. It is designed to provide estrogen plus progestin protection against endometrial hyperplasia.

How is AMABELZ dosed and used

Oral fixed-dose combination therapy intended for continuous use.
Clinical value drivers in this therapeutic category typically include regimen simplicity (fixed-dose), tolerability, and formulary placement rather than differentiated mechanism.

Market implications of “vasomotor symptoms” labeling

The indications are commoditized across multiple brands and generics.
Differentiation is often limited to tolerability, discontinuation rates, and contracting outcomes with pharmacy benefit managers (PBMs).

What is the Orange Book status of AMABELZ and which patents protect it?

Featured snippet answer: The investment-critical item is the FDA Orange Book listing for AMABELZ, including drug-substance and drug-product patents plus any method-of-use and change-of-label patents, each with expiration dates. Patent protection breadth determines the timeline for generic entry and litigation risk.

What to diligence in the Orange Book for AMABELZ

For each listed patent for AMABELZ, capture:

Patent type: drug substance, drug product, method of use
Expiration date (including pediatric extensions if listed)
Whether patents are listed for specific strengths (if applicable)
Whether any orphan exclusivity, 5-year exclusivity, 3-year exclusivity, or 180-day exclusivity triggers are relevant based on the NDA history
Whether Orange Book listings indicate a 505(b)(2) pathway reference to earlier active ingredients (common in HRT category)

Investment relevance

Generic entry is typically driven by ANDA filings and Paragraph IV challenges to Orange Book patents.
If AMABELZ has a thin “live” patent wall, the brand’s cashflow profile is time-limited to the remaining listed patent expirations.

(No Orange Book listing data is included here because complete patent-by-patent expiration and status fields were not provided.)

When does AMABELZ lose exclusivity and when could generics launch?

Featured snippet answer: Generic launch timing depends on the last remaining Orange Book patent expiration and any blocking exclusivity (for example, 180-day exclusivity tied to first-filer status) and any 30-month stay triggered by a Paragraph IV filing.

Exclusivity timeline mechanics that govern HRT branded cashflow

If an ANDA challenges a listed patent, FDA generally triggers a 30-month stay while litigation is pending (if required statutory conditions are met).
The “first generic” can delay full market penetration if it triggers 180-day exclusivity (unless forfeited by settlement terms or failure conditions).
The practical end date for brand protection is usually the later of:
- last Orange Book patent expiration for relevant claims
- relevant exclusivity periods tied to the NDA or reference product chain
- termination/expiration dates under any settlement agreement

Investment scenario framing

Base case: steady erosion after loss of exclusivity through contracts and authorized generic mechanics.
Bear case: faster entry if multiple patents are vulnerable or if generics settle quickly.
Bull case: longer protection if method-of-use or formulation/product patents remain strong and litigations extend.

(No patent-expiration or litigation dates were provided in the prompt, so a dated timeline cannot be computed.)

How strong is the patent estate for AMABELZ and what is the likely generic entry risk?

Featured snippet answer: In menopausal HRT, the patent estate often splits into (1) broad drug substance and formulation protections and (2) narrower product-specific or method-of-use claims. Risk depends on whether the remaining live patents include claims that a generic cannot “design around” without infringing.

Patent strength factors to underwrite

Claim scope: whether the patents cover core combination characteristics (dose ratios, formulation attributes) or only narrow embodiments
Anticipated “design-around” vectors: different excipients, tablet/capsule changes, alternate dosing regimens, or label carve-outs (depending on method-of-use claims)
Claim enforceability: litigation history, claim construction outcomes, and whether the patentee has survived multiple validity challenges in prior HRT disputes

Generic entry risk scoring model (what matters for investment)

High risk if:
- only short-dated patents remain
- patents are formulation-focused with predictable design-around options
- prior art is extensive for combination HRT
- method-of-use claims are weak and likely invalidated or easy to avoid by label
Lower risk if:
- key patents are near-monopoly on combination dose/formulation with non-trivial design-around barriers
- enforceability history is strong
- multiple independent patent families remain live beyond the brand’s remaining exclusivity window

What formulations are protected by AMABELZ and what product-specific barriers exist?

Featured snippet answer: For AMABELZ, the most investment-relevant formulation barriers are any Orange Book “drug product” patents that cover tablet core composition, coated-layer characteristics, dissolution profile, or manufacturability constraints that can make bioequivalence harder to replicate.

Typical HRT formulation patent categories (to map against Orange Book lists)

Tablet composition and excipient systems (including coating polymers)
Controlled release or dissolution specifications (if claimed)
Manufacturing process patents (if listed)
Stability and shelf-life related claims (if listed)

Manufacturing/IP barriers

If AMABELZ has manufacturing-specific patents, generic viability hinges on whether alternative processes avoid infringement while meeting FDA CMC and bioequivalence requirements.

What method-of-use patents apply to AMABELZ and how can generics avoid them?

Featured snippet answer: If AMABELZ has method-of-use patents, a generic label carve-out is the typical avoidance mechanism. The generic still must meet FDA requirements, but the label can be shaped to avoid the protected therapeutic regimen.

Method-of-use avoidance pathways commonly used

Adjusting language around patient selection, dosing schedule, or duration
Limiting indication statements to non-infringing subsets
Label alignment strategies used in FDA labeling negotiations

Investment implication

Strong method-of-use coverage can extend brand protection even after drug product patents expire, but only if the claims are enforceable and not easily avoided by label.

What patent litigation affects AMABELZ and are there Paragraph IV filings?

Featured snippet answer: The decisive factor for generic threats is whether ANDA sponsors have filed Paragraph IV certifications against listed Orange Book patents and whether the cases led to a settlement or a final judgment extending exclusivity.

What to track for litigation-driven entry

Patent(s) asserted in Paragraph IV notices
Court venue and case caption
Timeline of motions, Markman outcomes, and any summary judgment rulings
Settlement date and terms (including non-expiring injunctions, “authorized generic” timing, or market entry dates)

Business impact

Settlements can “schedule” generic launches at a predictable time or trade entry timing for consideration.

(No litigation docket information was provided in the prompt, so no case list can be reliably produced.)

How do settlements and authorized generics change AMABELZ’s investment outlook?

Featured snippet answer: In HRT categories, settlement agreements often allow generics to launch after a defined date, and authorized generics can accelerate brand share loss even when the brand’s labeled exclusivity period is still in flux.

Settlement terms that shift investor payoffs

Launch date of the first ANDA entrant
Whether an authorized generic can be launched earlier than full exclusivity expiry
Provisions that determine whether another filer is blocked
Any “no-AG” or “AG-permitted” terms

What to underwrite in a model

Speed to loss of average net price (Net-to-Gross) after generic entry
Expected share transition period (often rapid in mature HRT markets)
Channel structure: retail vs. mail order uptake for generic equivalents

(No specific settlement terms or parties were provided.)

What is the FDA regulatory pathway for AMABELZ and does it affect exclusivity?

Featured snippet answer: Regulatory pathway impacts whether the NDA benefits from application-specific exclusivity and how the reference product chain affects listed patent scope. For combination HRT products, AMABELZ may be tied to earlier active ingredients with established regulatory history.

Key regulatory items to include in diligence

NDA type (e.g., New Molecular Entity vs. listed drug update, or 505(b)(2) dependent)
Whether listed actives are already approved in the reference context
Whether any patent term adjustments (PTA) extend patent expirations
Whether any exclusivity is time-based and independent from the listed patents

(No NDA application number or pathway data was provided in the prompt.)

How does AMABELZ compare with other menopausal hormone therapies and what does it mean for pricing power?

Featured snippet answer: Compared with other oral estradiol/progestin regimens, branded pricing power in HRT typically erodes once generics and authorized generics are available. AMABELZ’s competitive position depends on formulary access, copay tiering, and switching behavior.

Competitive set to benchmark

Other branded estradiol/progestin combinations
Generic estradiol plus progestin equivalents
Distinct delivery systems (patches, gels) that compete on tolerability

Pricing power drivers

PBM preferred status
Therapeutic substitution tolerance by prescribers and patients
Persistency and discontinuation rates

(No AMABELZ sales, share, or contract data was provided.)

Commercial fundamentals: what revenue exposure does AMABELZ face from exclusivity loss?

Featured snippet answer: The main revenue exposure is the gap between the last listed protection date and the market’s willingness to switch to generic oral equivalents, amplified by authorized generic tactics.

Model inputs typically used for HRT cashflow

Time to generic entry: last patent expiration + stay/settlement schedule
Share decay curve: rate of switching after launch
Net price erosion: expected ASP decline for branded product after generic penetration
Additional pressure from competing delivery modalities (patch/gels)

(No financials were provided; a quantified revenue forecast cannot be constructed.)

Geographic coverage: is AMABELZ exclusivity US-only or does it extend internationally?

Featured snippet answer: US exclusivity and patent listings drive most litigation-linked investment scenarios for oral small molecules, but international filings can matter for manufacturing and marketing strategy and for parallel import dynamics.

What matters internationally

Whether the active combination is protected in major markets (EU, UK, Canada, Japan)
Whether data exclusivity or patent term adjustments differ by jurisdiction
Whether generics are launched earlier in other geographies and influence US timing through commercial spillover (rare but relevant in planning)

(No international regulatory/patent filing data was provided.)

Key Takeaways

AMABELZ is an oral estradiol/progestin hormone therapy for menopausal vasomotor symptoms and is exposed to category-wide generic substitution dynamics.
The investment thesis hinges on the remaining Orange Book patent and exclusivity landscape, plus whether any ANDA Paragraph IV challenges and settlements schedule generic entry.
In HRT, patent strength matters most where claims are hard to design around (combination-formulation or non-label-avoidable method claims).
Absent patent-by-patent Orange Book and litigation specifics, a decision-grade timeline for generic entry cannot be computed from the prompt alone.

FAQs

What happens to AMABELZ pricing and market share after the first generic ANDA launch?
Which Orange Book patent categories (drug substance, drug product, method of use) usually drive the longest protection for HRT combinations?
How do Paragraph IV 30-month stays and settlement dates typically affect branded HRT cashflow?
Do authorized generics materially accelerate AMABELZ revenue decline after patent expiration?
How can a generic avoid method-of-use claims for oral estradiol/progestin regimens without losing FDA approval?

References (APA)

No sources were cited because the prompt did not include AMABELZ FDA application identifiers, Orange Book patent listings, litigation dockets, or expiration/settlement details required for citation-grade support.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for AMABELZ